Intestine and Lower Gastrointestinal Tract · 18 August 2024

Fidaxomicin demonstrates lower recurrence rates than vancomycin.

Findings indicate that fidaxomicin and vancomycin have no significant differences in overall treatment efficacy for Clostridium difficile infection (CDI). However, fidaxomicin significantly reduced recurrence rates at 40-day (RR=0.52), 60-day (RR=0.38), and 90-day (RR=0.62) intervals compared to vancomycin. Vancomycin was shown to be more effective for severe CDI cases. In terms of long-term mortality, fidaxomicin also performed better over 60 days (RR=0.57).

Comparative Study by Zhao Z, Wu Y (…) Yang G et 3 al. in Medicine (Baltimore)

read the whole article in Medicine (Baltimore)

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

Br J Surg4 Nov 2026

Robot matches laparoscopy for rectal cancer survival

Five years after surgery for low rectal cancer, patients operated on robotically did as well as those operated on laparoscopically, according to a randomized trial from three Korean centres.

Ann Surg Oncol2 Nov 2026

Smoking linked to weaker rectal cancer response

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

All papers in Intestine and Lower Gastrointestinal Tract →